Accessibility StatementSkip Navigation Conference Call and Webcast Information: A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on November 6, 2025 and will remain accessible for one year via the webcast link above. Earnings Materials: Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast: ABOUT HAEMONETICS Haemonetics is a global medical technology company dedicated to i ...

Accessibility StatementSkip Navigation GALWAY, Ireland, Nov. 5, 2025 /PRNewswire/ --Â Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 18, 2025, for its second quarter of fiscal year 2026, which ended on Friday, October 24, 2025. Looking ahead, Medtronic plans to report its fiscal year 2026 third and fourth quarter results on Tuesday, February 17, 2026, and Wednesday, May 20, 2026, respectively. Confirmation and a ...

Accessibility StatementSkip Navigation SAN DIEGO, Nov. 5, 2025 /PRNewswire/ --Â The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases. Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committe ...

SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 2025 Stifel Healthcare conference on Wednesday, November 12, 2025, at 10:40 a.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.ou ...

Siemens Healthineers is preparing for the possibility that its biggest shareholder Siemens AG may reduce its stake in the medical technology company to less than 50%, its CFO said on Wednesday. ...

CollagenX is a potential addition to every case type currently addressed by Xtant's biologics portfolio, as well as procedures performed in other surgical disciplines. Sean Browne, President and CEO of Xtant Medical, stated, "The commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates our dedication to innovation in meeting the diverse needs of surgeons and patients. As one of the few fully vertically integrated regenerative medicine firms, ...

Accessibility StatementSkip Navigation YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: U.S. GAAP Results (U.S. dollars in thousands, except for per share data) results exclude share-based compensation and related tax adjustments. Management Comments "The third quarter progressed in ...

Higher comparable revenue stemming from the transformation program of its diagnostics business was offset by a hit from U.S. tariffs. ...

Accessibility StatementSkip Navigation FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revelloâ"¢ Vascular Covered Stent in patients with peripheral arterial disease (PAD). Continue Reading BD Achieves Milestone in AGILITY Study of Revel ...

文章核心观点 - 公司在第三季度保持增长势头，通过人工智能创新和长期合作伙伴关系推动业绩，在不确定的宏观环境下仍按计划推进 [2] - 公司重申对2025年全年业绩指引的信心，并预计利润率将处于指引范围的高端 [8][11] 集团及部门业绩 - 可比订单量增长8%，集团销售额达43亿欧元，可比销售额增长3.3%，所有业务部门均实现增长 [4][8] - 调整后息税摊销前利润率扩大50个基点至12.3%，主要受销售额增长、有利的产品组合效应和生产力提升推动，抵消了关税增加的影响 [4][8] - 自由现金流增加至1.72亿欧元，营运现金流为3.27亿欧元 [4][8] - 诊断与治疗业务可比销售额增长1.3%，调整后息税摊销前利润率为11.8%，下降80个基点 [5] - 互联关护业务可比销售额增长5.1%，调整后息税摊销前利润率改善410个基点至11.4% [5] - 个人健康业务可比销售额增长10.9%，调整后息税摊销前利润率提升60个基点至17.1% [6] 创新亮点 - 在美国推出Lumea IPL（强脉冲光脱毛仪），该品牌为全球第一，上市初期即获得强劲的消费者关注 [9] - 发布放射治疗突破性产品，包括先进的Rembra RT和Areta RT CT扫描仪，并在北美推出无氦BlueSeal RT MR [9] - 推出新一代心血管超声系统Transcend Plus、EPIQ CVx和Affiniti CVx，包含26个获FDA批准的心血管超声AI应用，为行业最多 [9] 生产力与成本管理 - 严格的成本管理和稳健的生产力计划在本季度带来2.22亿欧元的节约 [10] - 公司将执行为期三年、总额25亿欧元的生产力计划，其中2025年计划实现8亿欧元的节约 [10] 合作伙伴关系与可持续发展 - 与美国加州领先医疗系统（如橙郡Hoag医院和圣地亚哥Rady儿童医院）签署长期企业监护即服务合作伙伴关系 [14] - 公司到2045年实现净零排放的科学基础目标已获科学碳目标倡议正式验证 [14] - 与印度尼西亚卫生部的里程碑式协议进入实施阶段，首套Azurion系统正在东爪哇安装 [3]